Dr. Epperla on Treatment Following Ibrutinib in MCL

Narendranath Epperla, MBBS, MS
Published: Wednesday, Nov 01, 2017



Narendranath Epperla, MBBS, MS, hematologist, The Ohio State University (OSU) Comprehensive Cancer Center, assistant professor in internal medicine, OSU, discusses the next steps for patients with mantle cell lymphoma (MCL) who fail ibrutinib (Imbruvica).

Patients who fail ibrutinib have poor results, with the median survival being a few months. As of today, there is no breakthrough treatment for patients who fail ibrutinib, which is an urgent unmet need, states Epperla.

There are ongoing combination trials investigating ibrutinib with CDK4/6 inhibitors to determine if that can overcome resistance, explains Epperla.
 


Narendranath Epperla, MBBS, MS, hematologist, The Ohio State University (OSU) Comprehensive Cancer Center, assistant professor in internal medicine, OSU, discusses the next steps for patients with mantle cell lymphoma (MCL) who fail ibrutinib (Imbruvica).

Patients who fail ibrutinib have poor results, with the median survival being a few months. As of today, there is no breakthrough treatment for patients who fail ibrutinib, which is an urgent unmet need, states Epperla.

There are ongoing combination trials investigating ibrutinib with CDK4/6 inhibitors to determine if that can overcome resistance, explains Epperla.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 1st Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesJan 30, 20182.0
Medical Crossfire®: The Expanding Role of PARP Inhibitors in the Treatment of Ovarian Cancers – Current Strategies and Future DirectionJan 30, 20181.5
Publication Bottom Border
Border Publication
x